IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Key Takeaways IONS gained 5.6% after the FDA gave Breakthrough Therapy status to ION582 for Angelman syndrome.The designation followed phase I/II HALOS data showing broad functional gains and good safety.IONS has begun the phase III REVEAL study for ION582 in children and adults with Angelman syndrome.Ionis Pharmaceuticals (IONS) announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological disease. ...